TY - JOUR
T1 - Association Between Direct Oral Anticoagulant Score and Bleeding Events in Patients With Atrial Fibrillation Following Transcatheter Aortic Valve Replacement
T2 - A Retrospective Multicenter Cohort Study
AU - the OCEAN-TAVI Investigators
AU - Harano, Yoshihiro
AU - Yamamoto, Masanori
AU - Shimura, Tetsuro
AU - Okubo, Munenori
AU - Koyama, Yutaka
AU - Yamaguchi, Ryo
AU - Kagase, Ai
AU - Tokuda, Takahiro
AU - Yashima, Fumiaki
AU - Shirai, Shinichi
AU - Tada, Norio
AU - Naganuma, Toru
AU - Yamawaki, Masahiro
AU - Yamanaka, Futoshi
AU - Mizutani, Kazuki
AU - Noguchi, Masahiko
AU - Ueno, Hiroshi
AU - Takagi, Kensuke
AU - Ohno, Yohei
AU - Izumo, Masaki
AU - Nishina, Hidetaka
AU - Asami, Masahiko
AU - Otsuka, Toshiaki
AU - Watanabe, Yusuke
AU - Hayashida, Kentaro
N1 - Publisher Copyright:
© 2024 The Author(s).
PY - 2024/11/19
Y1 - 2024/11/19
N2 - BACKGROUND: The Direct Oral Anticoagulant (DOAC) Score can predict bleeding risk in patients with atrial fibrillation taking DOACs; however, it lacks external validation. Therefore, this study aimed to assess the association between the DOAC Score and bleeding events in patients with atrial fibrillation who underwent transcatheter aortic valve replacement. METHODS AND RESULTS: This retrospective multicenter cohort study included patients with atrial fibrillation who underwent tran-scatheter aortic valve replacement, as registered in a Japanese multicenter registry. The primary end point was the incidence of bleeding. Patients were categorized based on their DOAC Score: low and moderate-(≤7 points), high-(8–9 points), and very high-risk (≥10 points) groups. Among 1230 patients (mean age 84.6±5.1 years; 457 men), 465 (37.8%) received a vitamin K antagonist, and the remaining patients received DOACs. The low and moderate-, high-, and very high-risk groups included 380 (30.1%), 497 (40.4%), and 353 patients (28.7%), respectively. The 3-year cumulative incidence of all bleeding events was significantly different among the 3 groups (low and moderate risk: 6.6%, high risk: 6.9%, and very high risk: 14.0%; P<0.01). Multivariable Cox regression analysis revealed that significant increments in the DOAC Score were associated with a risk of all bleeding events at 3 years in the overall cohort (hazard ratio [HR], 1.22 [95% CI, 1.08–1.38]; P<0.01), in the DOAC cohort (HR, 1.20 [95% CI, 1.01–1.42]; P=0.04), and in the vitamin K antagonist cohort (HR, 1.25 [95% CI, 1.04–1.50]; P=0.02). CONCLUSIONS: The DOAC Score was significantly associated with bleeding events in patients with atrial fibrillation after tran-scatheter aortic valve replacement, aiding in clinical decision-making for anticoagulant management. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023585; Unique identifier: UMIN000020423.
AB - BACKGROUND: The Direct Oral Anticoagulant (DOAC) Score can predict bleeding risk in patients with atrial fibrillation taking DOACs; however, it lacks external validation. Therefore, this study aimed to assess the association between the DOAC Score and bleeding events in patients with atrial fibrillation who underwent transcatheter aortic valve replacement. METHODS AND RESULTS: This retrospective multicenter cohort study included patients with atrial fibrillation who underwent tran-scatheter aortic valve replacement, as registered in a Japanese multicenter registry. The primary end point was the incidence of bleeding. Patients were categorized based on their DOAC Score: low and moderate-(≤7 points), high-(8–9 points), and very high-risk (≥10 points) groups. Among 1230 patients (mean age 84.6±5.1 years; 457 men), 465 (37.8%) received a vitamin K antagonist, and the remaining patients received DOACs. The low and moderate-, high-, and very high-risk groups included 380 (30.1%), 497 (40.4%), and 353 patients (28.7%), respectively. The 3-year cumulative incidence of all bleeding events was significantly different among the 3 groups (low and moderate risk: 6.6%, high risk: 6.9%, and very high risk: 14.0%; P<0.01). Multivariable Cox regression analysis revealed that significant increments in the DOAC Score were associated with a risk of all bleeding events at 3 years in the overall cohort (hazard ratio [HR], 1.22 [95% CI, 1.08–1.38]; P<0.01), in the DOAC cohort (HR, 1.20 [95% CI, 1.01–1.42]; P=0.04), and in the vitamin K antagonist cohort (HR, 1.25 [95% CI, 1.04–1.50]; P=0.02). CONCLUSIONS: The DOAC Score was significantly associated with bleeding events in patients with atrial fibrillation after tran-scatheter aortic valve replacement, aiding in clinical decision-making for anticoagulant management. REGISTRATION: URL: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023585; Unique identifier: UMIN000020423.
KW - atrial fibrillation
KW - bleeding
KW - DOAC Score
KW - transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85210105627&partnerID=8YFLogxK
U2 - 10.1161/JAHA.124.036417
DO - 10.1161/JAHA.124.036417
M3 - 学術論文
C2 - 39508173
AN - SCOPUS:85210105627
SN - 2047-9980
VL - 13
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 22
M1 - e036417
ER -